Varicella Zoster Infection Treatment Market Is Expected to Grow at an Amazing Rate, Reaching USD 2.04 Billion by 2028, with a CAGR of 4.1%. | FMI

Varicella Zoster Infection Treatment Market

The fight against shingles, a painful reactivation of the chickenpox virus, is gaining traction in the treatment market. The global Varicella Zoster Infection Treatment Market is projected to reach a significant USD 2.5 billion by 2028, reflecting a steady growth of CAGR of 4.1%. This upsurge builds on a market value of over USD 1.61 billion in 2022

Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, hemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorized by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population.

Request a Sample Research Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

To cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships to make use of the technology of the other leading companies and are also focussing on research and development.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and fetal risks of varicella-zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Unbeatable Deals – Claim Your Discount Now.
https://www.futuremarketinsights.com/request-discount/rep-gb-6466

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Varicella Zoster Infection Treatment Market Key Players:

• Novartis AG,
• Pfizer Inc.,
• Abbott Laboratories,
• Sun Pharmaceuticals Industries Ltd.,
• Valeant Pharmaceuticals International Inc.,
• Teva Pharmaceutical Industries Ltd.,
• Dr. Reddy’s Laboratories, ltd.,
• Mylan N.V.  and
• GlaxoSmithKline

Access Your Customized Report Today.
https://www.futuremarketinsights.com/customization-available/rep-gb-6466

Varicella Zoster Infection Treatment Market Segmentation – by Category

By Drug Type:

• Acyclovir
• Valacyclovir
• Famciclovir

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube